Stock Events

Stock Events

Hikma Pharmaceuticals

€0

0

+€0+0% Today

Statistics

Day High

-

Day Low

-

52W High

-

52W Low

-

Volume

-

Avg. Volume

-

Mkt Cap

0

P/E Ratio

-

Dividend Yield

-

Dividend

-

Upcoming

Earnings

26FebExpected

Q4 2025

0.91

1.24

1.58

1.91

Expected EPS

0.911462124

Actual EPS

N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow H5P.MU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Teva- Pharmaceutical Industries

Teva Pharmaceutical Industries is a global leader in generic and specialty medicines, directly competing with Hikma in the generics and branded drugs markets.

Novartis is a large multinational pharmaceutical company with a strong presence in generic drugs through its Sandoz division, making it a direct competitor to Hikma.

Pfizer is a global pharmaceutical corporation with a broad portfolio that includes generic drugs, competing with Hikma in various therapeutic areas.

AbbVie, known for its significant research-based pharmaceuticals, competes with Hikma in the specialty pharmaceuticals market, particularly in areas like immunology and oncology.

Johnson & Johnson

Johnson & Johnson, through its pharmaceutical segment Janssen, competes with Hikma in the development and marketing of pharmaceuticals for various therapeutic areas.

Merck & Co. is a global healthcare company that competes with Hikma in the development, manufacturing, and marketing of pharmaceuticals and vaccines.

GlaxoSmithKline is a global healthcare company that competes with Hikma in the pharmaceutical and vaccines sectors, with a broad portfolio of products.

Sanofi is a global pharmaceutical company that competes with Hikma in the areas of generics, specialty care, and vaccines.

AstraZeneca is a global, science-led biopharmaceutical business that competes with Hikma in the development and commercialization of prescription medicines across multiple therapy areas.

About

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, specialty, and branded pharmaceutical products. The company operates through three segments: Injectables, Hikma Rx, and Branded. The Injectables segment provides generic and specialty injectable products primarily for use in hospitals. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The Hikma Rx segment offers oral, respiratory, and other generic and specialty products for the retail market. It provides its products in various therapeutic areas, including respiratory, oncology, and pain management. The company also offers its products in solid, semi-solid, liquid, and injectable dosage forms. It operates in the United Kingdom, Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, United Kingdom.

Show more...

CEO

H.E Said Samih Taleb Darwazah

Employees

9400

Country

United Kingdom

ISIN

GB00B0LCW083

Listings

0 Comments

Share your thoughts

FAQ

What is Hikma Pharmaceuticals stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on exchange Hikma Pharmaceuticals stocks are traded under the ticker H5P.MU.

When is the next Hikma Pharmaceuticals earnings date?▼

Hikma Pharmaceuticals is going to release the next earnings report on August 06, 2026.

How many employees does Hikma Pharmaceuticals have?▼

As of April 12, 2026, the company has 9,400 employees.

In which sector is Hikma Pharmaceuticals located?▼

Hikma Pharmaceuticals operates in the Health & Wellness sector.

When did Hikma Pharmaceuticals complete a stock split?▼

Hikma Pharmaceuticals has not had any recent stock splits.

Where is Hikma Pharmaceuticals headquartered?▼

Hikma Pharmaceuticals is headquartered in London, United Kingdom.